Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: AVE1642|DRUG: Fulvestrant
Sponsor: Sanofi